undamentalytics Newsletter
Sign in

Celularity Inc (CELU) stock

Add to watchlist

Add holding +

NASDAQ: CELU Nasdaq Biotechnology

D Fundamentals grade

Celularity Inc is a US-listed company in the biotechnology industry. Its financial year ends in December.

Stock price today

Loading chart…

Third-party market data · may be delayed

Model estimate per share

~$0.8

Price-to-sales vs peers

Base case. Range ~$0.8–$6.0. Sales per share times peers' typical price-to-sales; used only when earnings are negative.

Price vs value

No Buy/Hold/Sell rating is issued: only 1 valuation models apply; a rating needs 3.

Celularity Inc valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Funds13 adding, 8 cuttingOf 1 active managers that changed their stake, 1 added; quarter to June 30, 2026Fund buyers and sellers

Value diary

Our note on each quarter Celularity files

Where Celularity stands after its latest 10-Q

Revenue for the twelve months to June 2026 was $19m, down 58.1% on a year earlier, a smaller fall than the 62.8% decline a quarter earlier. That puts it 103 of 122 for growth among the biotechnology companies we cover. Free-cash-flow margin fell to -80.1% from -20.7% a year earlier. Operating margin narrowed to -264.3% from -105.8%. The diluted share count is up 24.7% on a year earlier, which dilutes existing holders. Against its peers on growth, profitability, cash generation and balance sheet, it grades D. It passes 0 of our 2 financial-health checks. Our price-to-sales vs peers value is $1.64 a share.

Source: 10-Q filed October 20, 2026 on SEC EDGAR · Financials · Valuation

Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.

The Fundamentalytics view

Celularity Inc's trailing-twelve-month revenue fell 58.1% year on year, with a free-cash-flow margin of -80.1%. Where it lags: gross margin of 19.2% ranks 73 of 75 biotechnology companies we cover.

Current signal Net income rising while operating cash flow falls: TTM net income grew 37.8% while operating cash flow fell 251.0% — earnings and cash are telling different stories.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

Nothing in Celularity Inc's latest figures clears our strength thresholds.

Things to watch

  • Revenue shrinking. Revenue fell 58.1% over the last 12 months.
  • Loss-making. Operating margin is -264.3%: costs exceed revenue.
  • Margins narrowing. Operating margin is down 158.5 points on a year ago.
  • Burning cash. Free cash flow was -80.1% of revenue over the last 12 months.
  • Heavy stock-based pay. Stock pay equals 66.5% of revenue, against a median of 19.2% for biotechnology companies we cover: a real cost that cash-flow figures leave out.
  • Share dilution. Diluted shares rose 24.7% in a year.

Latest results: FY2026 Q2

Filed October 20, 2026
Earnings per share
-$2.70 against an average estimate of -$0.30: missed by 800.0%
Revenue
$5m, down 5.3% on a year earlier

Celularity's figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day+0.4%
  • 1 week+7.1%
  • 1 month-49.8%
  • This year-27.7%
  • 1 year-58.8%
  • 5 years-98.9%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

Revenue (TTM)
$18.7M
Operating margin
-264.3%
Net margin
-245.7%
EPS (TTM, diluted)
$-1.60

Growth

Revenue growth
−58.1%
Change in growth rate
+4.6 pts
Share count change
+24.7%

Cash

Free cash flow (TTM)
-$15M
FCF margin
-80.1%
Stock pay % of revenue
66.5%

Earnings

Last results
May 9, 2025

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Announcement
  2. Leadership
  3. Leadership
  4. Announcement
  5. Leadership

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Celularity Inc valuation models and calculator

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: only 1 valuation models apply; a rating needs 3.

Valuation models

We value Celularity Inc as an operating company, with every model that fits that kind of business. Cost of equity 12.3%: the 10-year Treasury yield (4.9%) plus a beta of 1.64 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. — Does not apply: revenue and margins don't support a positive value
Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. — Does not apply: no positive earnings in the latest twelve months
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. — Does not apply: book value or earnings not available
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. — Does not apply: return on equity is not positive
Price-to-sales vs peers Sales per share times peers' typical price-to-sales; used only when earnings are negative. ~$0.8 ~$1.8–$6.0 Included, half weight
Combined value Weighted average of the models that apply: the primary model (revenue-to-maturity model) counts double. Models more than 5x or less than 0.2x the share price, or more than 3x away from the other models' median, are left out. ~$0.8 ~$0.8–$6.0 1 model

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Celularity Inc with Biotechnology in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

Valuation multiples over time Market data may be delayed

At fiscal year end 202020212022202320242025Now
Share price$110.00$51.20$12.90$2.47$2.08$1.11$0.80
Market value$203m$343m$193m$44m$46m$28m$23m
+ Net debt (− = net cash)−$54m−$37m$24m$56m−$738000$28m$33m
Enterprise value$148m$306m$217m$100m$45m$56m$56m
Multiples
Price / sales 14.2x16.1x10.8x1.9x0.8x1.1x1.2x
Price / earnings ——13.6x————
Price / free cash flow ———————
EV / EBITDA ———————

Market value uses the period's diluted share count; figures for each fiscal year use that year's results and the price at year end. "Now" uses today's price and the last twelve months.

Moat

18 /100

Weak moat

How hard Celularity's competitive advantage looks for rivals to wear away, judged from 7 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.

  • Returns on capital 0 / 20

    Net income has been a median -47.7% of total assets over 7 years.

  • Pricing power 9 / 20

    Gross margin has been a median 49.4%, moving by 23.0 percentage points (standard deviation) across 6 years.

  • Durability 10 / 20

    Operating margin has been a median -253.3%; its worst year was -792.9%.

  • Cash conversion 0 / 20

    Free cash flow was positive in 0 of 5 years, at a median -80.1% of revenue.

AI disruption exposure: Medium. In this industry, AI could change how the product is made or sold, without replacing the core asset. The score above includes a 5-point deduction for that exposure (24 before it).

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Analysts' consensus

No analyst estimates are published for Celularity Inc: too few analysts cover it.

Earnings against estimates

Quarter toEstimateActualSurprise
Jun 2023 −$0.30 −$2.70 −800.0%
Mar 2023 −$2.40 −$4.10 −70.8%

Adjusted EPS as companies report it, against the average analyst estimate.

Management guidance

Earnings release, May 9, 2025

No numeric guidance in Celularity Inc's latest earnings release (filed May 9, 2025). Some companies give their outlook only on the earnings call.

Positioning

Short interest
4.3%
of tradable shares
Days to cover
3.17
at average volume
Short interest, 1 month
−46%
to October 15, 2026
Held by institutions
11%
of shares
Held by insiders
33.3%
of shares
Employees
115
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

What moved the share price

Last 12 months −58.8%

$1.95 on October 31, 2025 to $0.80

ThenNowEffect
Revenue (last 12 months) $45m $19m −58.1%
P/S multiple 1.0x 1.2x +22.7%
Share count 23m 29m −19.8%

Biggest factor: revenue. Loss-making at one end, so the split uses price/sales.

The effects multiply back to the price change exactly. Results are the last 12 months as known on each date (filings assumed public 45 days after quarter end).

Return and risk by year

Calendar year 202120222023202420252026 to date
Return
CELU−54%−75%−81%−16%−47%−28%
Industry peers (median)−35%−56%−17%−29%−5%−26%
S&P 500+29%−18%+26%+25%+18%+11%
Months that ended higher
CELU25%33%17%58%42%64%
S&P 50075%42%67%75%75%46%
Largest fall from a high during the year
CELU−62%−92%−87%−80%−73%−64%
S&P 500−5%−25%−10%−8%−19%−9%

Worst fall since August 8, 2019: 100% from April 28, 2022 to June 30, 2026. Getting back needed a 21489% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$0.60 – $2.10
From 52-week high
−61.8%
vs 50-day average
−39.1%
vs 200-day average
−25.9%
Volatility (1 year)
170%
Beta vs S&P 500
2.02

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
7 up, 4 down
typical move ±19.5%
After a week
3 up, 8 down
typical move ±16.0%
After a month
5 up, 6 down
typical move ±29.8%
Results releasedNext dayS&P 500 next day5 days21 days
May 9, 2025 −8.4% +3.2% +22.9% +21.1%
November 7, 2024 +144.8% +1.2% +55.2% +58.6%
October 25, 2024 −21.6% +0.3% −33.9% +37.6%
May 21, 2024 +10.8% 0.0% −4.5% −2.9%
January 9, 2024 0.0% +0.4% −24.8% +60.0%
November 10, 2022 +9.1% +6.5% −5.4% −11.8%
August 10, 2022 +1.9% +2.1% −5.8% −21.4%
May 16, 2022 +3.0% +1.6% −3.3% −42.9%
March 31, 2022 +4.1% −1.3% +11.4% +36.5%
November 12, 2021 −5.9% +0.8% −3.6% −31.8%
August 16, 2021 +5.4% −0.4% −5.4% −2.8%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Celularity Inc in five measures

Fundamentals grade D
Growth Profitability Cash Balance sheet

Growth, profitability, cash generation and balance sheet are percentiles against the companies we cover in the same industry, from SEC filings (100 = best). Value compares the share price with our modelled value range (50 = at our base value; higher = cheaper). A description of reported data and our model — not a quality score or advice.

Fundamentals

Revenue (TTM) Celularity Inc
$0 $20M $40M $60M FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Revenue (TTM), FY23 Q3: $14.8M Revenue (TTM), FY23 Q4: $22.8M Revenue (TTM), FY24 Q1: $33.5M Revenue (TTM), FY24 Q2: $42.7M Revenue (TTM), FY24 Q3: $48.2M Revenue (TTM), FY24 Q4: $54.2M Revenue (TTM), FY25 Q1: $51M Revenue (TTM), FY25 Q2: $44.6M Revenue (TTM), FY25 Q3: $40.6M Revenue (TTM), FY25 Q4: $26.6M Revenue (TTM), FY26 Q1: $19M Revenue (TTM), FY26 Q2: $18.7M $18.7M

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue (TTM)
FY23 Q3 $14.8M
FY23 Q4 $22.8M
FY24 Q1 $33.5M
FY24 Q2 $42.7M
FY24 Q3 $48.2M
FY24 Q4 $54.2M
FY25 Q1 $51M
FY25 Q2 $44.6M
FY25 Q3 $40.6M
FY25 Q4 $26.6M
FY26 Q1 $19M
FY26 Q2 $18.7M
Revenue growth, TTM YoY Celularity Inc
-100% 0% 100% 200% 300% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Revenue growth, TTM YoY, FY23 Q3: -20.9% Revenue growth, TTM YoY, FY23 Q4: 26.7% Revenue growth, TTM YoY, FY24 Q1: 109.8% Revenue growth, TTM YoY, FY24 Q2: 182.0% Revenue growth, TTM YoY, FY24 Q3: 225.9% Revenue growth, TTM YoY, FY24 Q4: 138.1% Revenue growth, TTM YoY, FY25 Q1: 52.1% Revenue growth, TTM YoY, FY25 Q2: 4.5% Revenue growth, TTM YoY, FY25 Q3: -15.8% Revenue growth, TTM YoY, FY25 Q4: -51.0% Revenue growth, TTM YoY, FY26 Q1: -62.8% Revenue growth, TTM YoY, FY26 Q2: -58.1% -58.1%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue growth, TTM YoY
FY23 Q3 -20.9%
FY23 Q4 26.7%
FY24 Q1 109.8%
FY24 Q2 182.0%
FY24 Q3 225.9%
FY24 Q4 138.1%
FY25 Q1 52.1%
FY25 Q2 4.5%
FY25 Q3 -15.8%
FY25 Q4 -51.0%
FY26 Q1 -62.8%
FY26 Q2 -58.1%
Operating margin (TTM) Celularity Inc
-1500% -1000% -500% 0% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Operating margin (TTM), FY23 Q3: -1272.1% Operating margin (TTM), FY23 Q4: -844.4% Operating margin (TTM), FY24 Q1: -405.1% Operating margin (TTM), FY24 Q2: -242.4% Operating margin (TTM), FY24 Q3: -32.7% Operating margin (TTM), FY24 Q4: -70.7% Operating margin (TTM), FY25 Q1: -81.4% Operating margin (TTM), FY25 Q2: -105.8% Operating margin (TTM), FY25 Q3: -119.6% Operating margin (TTM), FY25 Q4: -230.9% Operating margin (TTM), FY26 Q1: -321.3% Operating margin (TTM), FY26 Q2: -264.3% -264.3%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Operating margin (TTM)
FY23 Q3 -1272.1%
FY23 Q4 -844.4%
FY24 Q1 -405.1%
FY24 Q2 -242.4%
FY24 Q3 -32.7%
FY24 Q4 -70.7%
FY25 Q1 -81.4%
FY25 Q2 -105.8%
FY25 Q3 -119.6%
FY25 Q4 -230.9%
FY26 Q1 -321.3%
FY26 Q2 -264.3%
FCF margin (TTM) Celularity Inc
-600% -400% -200% 0% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 FCF margin (TTM), FY23 Q3: -440.7% FCF margin (TTM), FY23 Q4: -174.5% FCF margin (TTM), FY24 Q1: -86.4% FCF margin (TTM), FY24 Q2: -50.1% FCF margin (TTM), FY24 Q3: -26.9% FCF margin (TTM), FY24 Q4: -12.1% FCF margin (TTM), FY25 Q1: -23.1% FCF margin (TTM), FY25 Q2: -20.7% FCF margin (TTM), FY25 Q3: -32.5% FCF margin (TTM), FY25 Q4: -74.6% FCF margin (TTM), FY26 Q1: -79.7% FCF margin (TTM), FY26 Q2: -80.1% -80.1%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period FCF margin (TTM)
FY23 Q3 -440.7%
FY23 Q4 -174.5%
FY24 Q1 -86.4%
FY24 Q2 -50.1%
FY24 Q3 -26.9%
FY24 Q4 -12.1%
FY25 Q1 -23.1%
FY25 Q2 -20.7%
FY25 Q3 -32.5%
FY25 Q4 -74.6%
FY26 Q1 -79.7%
FY26 Q2 -80.1%

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-K/A, 10-Q. Generated November 3, 2026. Definitions in our methodology.

Financial statements

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2020 Dec 2020 2021 Dec 2021 2022 Dec 2022 2023 Dec 2023 2024 Dec 2024 2025 Dec 2025 LTM Jun 2026
Income
Revenue 14 21 18 23 54 27 19
Gross profit 9 12 −2 7 39 6 4
EBITDA −144 −100 −16 −183 −30 −54 −43
Operating income −152 −109 −26 −192 −38 −61 −49
Net income −208 −100 14 −196 −58 −92 −46
Diluted EPS −$113.10 −$14.90 $0.95 −$11.02 −$2.64 −$3.59 −$1.60
Growth (year on year)
Revenue — +49.4% −15.7% +26.7% +138.1% −51.0% −58.1%
Net income — — — <−999% — — —
Diluted EPS — — — <−999% — — —
Margins
Gross margin 65.5% 54.8% −9.4% 29.7% 72.4% 24.4% 19.2%
EBITDA margin <−999% −469.8% −89.9% −803.5% −56.1% −203.4% −232.0%
Operating margin <−999% −511.2% −142.4% −844.4% −70.7% −230.9% −264.3%
Net margin <−999% −469.3% 79.0% −862.0% −106.8% −345.4% −245.7%
Free-cash-flow margin −637.5% −545.1% −796.2% −174.5% −12.1% −49.9% −47.8%
Cash flow
Cash from operations −63 −110 −138 −39 −6 −13 −9
Capital spending 28 6 5 1 0 0 0
Free cash flow −91 −116 −143 −40 −7 −13 −9
Stock-based pay 4 40 16 0 12 11 12
Free cash flow after stock pay −95 −156 −159 −40 −18 −24 −21
Balance sheet
Cash 54 37 14 0 1 6 1
Total debt 0 0 38 56 0 34 34
Net debt (negative = net cash) −54 −37 24 56 −1 28 33
Diluted shares 2m 7m 15m 18m 22m 26m 29m
Returned to shareholders
Buybacks 0 — — — — — —
Total returned 0 — — — — — —

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Financial health

0 of 2 checks passed · June 30, 2026
What it owns · $96m
Short-term assets $6mLonger-term assets $90m
What it owes, and who funded it · $132m
Short-term liabilities $60mLonger-term liabilities $72mShareholders' equity $-36m
  • Short-term assets cover short-term liabilities $6m of assets due within a year against $60m of liabilities due within a year.
  • Short-term assets cover long-term liabilities $6m short-term assets against $72m of longer-dated liabilities.
  • More cash than debt Cash or debt not separately reported. Not assessable.
  • Debt below 40% of shareholders' equity Equity or debt not reported. Not assessable.
  • Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
  • A year's operating cash flow covers at least 20% of debt Cash flow or debt not reported. Not assessable.
  • Operating profit covers interest at least five times over Interest not separately reported. Not assessable.

From Celularity Inc's latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Dividends, buybacks and capital spending

Diluted share count
+24.7%
year over year
R&D spending
69.5%
of revenue
Sales & admin spending
206.1%
of revenue
Days sales outstanding
92 days
receivables vs revenue

Competitors: side by side with peers

Closest by revenue in biotechnology
Last 12 months unless stated CELU CTMX SCYX PRQR KROS JANX Median
Revenue, last 12 months $19m $18m $19m $18m $15m $24m $56m
Revenue growth, last 12 months −58.1% −87.0% 489.8% −12.1% −93.6% >999% 12.6%
Revenue growth, 3-year average 7.2% −38.7% −47.9% — — 45.7% 13.7%
Revenue growth, latest quarter −5.3% −92.4% −82.8% — −100.0% >999% 10.2%
Gross margin 19.2% — 26.0% — — — 82.9%
Operating margin −264.3% −476.2% −117.6% −273.1% −682.3% −598.1% −189.4%
Operating margin, 3-year average −204.2% −146.9% −592.1% — <−999% <−999% −363.5%
Net margin −245.7% −435.2% −53.3% −265.2% −559.2% −427.5% −169.8%
Cash from operations / revenue −47.8% −450.3% −69.3% −331.9% −322.7% −171.9% −168.0%
Free-cash-flow margin −80.1% −450.7% −69.3% −338.3% −326.1% −174.7% −162.4%
Free-cash-flow margin, 3-year average −50.3% −192.6% −304.8% — <−999% <−999% −310.0%
Stock pay / revenue 66.5% 55.4% 12.3% 25.2% 153.8% 153.7% 20.0%
Change in share count 24.7% 88.7% 1.9% 22.4% −31.6% 6.2% 8.2%

Median of all 184 companies we cover in biotechnology. Shaded: best of the six on that line (lowest for stock pay and share-count growth). 3-year figures average the last three 12-month periods; 3-year growth is compound annual. Source: SEC filings.

Peer comparison

184 biotechnology companies
Measure Company Peer median Rank
Revenue growth Growth -58.1% 12.6% 146 of 172
Change in growth rate Growth +4.6pp -0.1pp 54 of 172
Gross margin Profitability 19.2% 82.4% 73 of 75
Operating margin Profitability -264.3% -189.4% 100 of 175
Net margin Profitability -245.7% -157.3% 102 of 180
Free-cash-flow margin Cash generation -80.1% -145.4% 78 of 176
Stock pay as % of revenue Cash generation 66.5% 19.2% 124 of 179
Long-term debt as % of assets Balance sheet 31.5% 20.6% 56 of 78
Change in share count Balance sheet 24.7% 7.9% 122 of 156
Days sales outstanding Balance sheet 92 days 75 days 61 of 100

Rank 1 = best in the group (for spending, debt and dilution, lower ranks first).

Where the revenue comes from

Fiscal year to December 31, 2025
Segments
Line of business Revenue Share YoY
Degenerative Disease $17.3M 65.2% ▼ 64.2%
Biobanking $5.4M 20.5% ▲ 5.7%
Cell Therapy $3.8M 14.3% ▲ 453.3%
Products and services
Line of business Revenue Share YoY
Products $13.2M 49.6% ▼ 62.7%
License Royalty and Other $7.9M 29.9% ▼ 42.2%
Services $5.4M 20.5% ▲ 5.7%

From Celularity Inc's 10-K filed April 30, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.

Who owns it

Funds buying and selling
Reported value
$2.4M
Institutions reporting
39
Shares held vs prior quarter
▲ 1.5%
Positions opened / closed
4 / 4

Top buyers and sellers, Q2 2026: 13 institutions bought and 8 sold ; the biggest buyer was Citadel Advisors LLC (+99K shares) and the biggest seller Blackrock, Inc (−51K). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
C V Starr & Co Inc $1.6M 764K 64.8% 0.0%
Vanguard Capital Management LLC $371,421 621K 15.2% 0.0%
Geode Capital Management, LLC $99,957 167K 4.1% ▼ 12.5%
Citadel Advisors LLC $59,224 99K 2.4% New
Vanguard Fiduciary Trust Co $47,765 80K 2.0% 0.0%
Blackrock, Inc. $45,655 76K 1.9% ▼ 40.1%
State Street Corp $34,577 58K 1.4% 0.0%
HRT Financial LP $33,000 57K 1.4% ▲ 342.7%
Northern Trust Corp $26,405 44K 1.1% 0.0%
Biltmore Family Office, LLC $20,927 35K 0.9% 0.0%
Hb Wealth Management, LLC $19,082 32K 0.8% ▼ 21.0%
Keynote Financial Services LLC $17,889 30K 0.7% ▲ 2.0%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Celularity Inc's complete shareholder register. Values are as reported by the filers .

Insider trading activity

Full insider history and chart
Insider purchases History → $0 0 trades by 0 insiders, last 12 months Insider sales History → $0 0 trades by 0 insiders
Net ▲ $0 net buying

No open-market insider trades reported in the last 12 months.

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

  • May 9, 2025
  • November 7, 2024
  • October 25, 2024
  • May 21, 2024
  • January 9, 2024
  • November 10, 2022

Recent SEC filings

Data status

When each part of this page on Celularity Inc was last updated.

DataLast updatedSource
Share priceExchange closing prices
Financial statementsSEC 10-K and 10-Q filings
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Celularity Inc in brief

What does Celularity Inc do?
Celularity Inc is a US-listed company in the biotechnology industry. Its financial year ends in December.
What is Celularity Inc's stock ticker?
Celularity Inc trades under the ticker CELU on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
What is Celularity Inc's revenue, and how fast is it growing?
Over its most recent trailing twelve months, Celularity Inc reported revenue of $18.7M, 58.1% lower than a year earlier, according to its SEC filings.
What is Celularity Inc's free cash flow?
Celularity Inc's free-cash-flow margin is -80.1% of revenue over the trailing twelve months, ranking 78 of the 176 biotechnology companies we cover.
Who are Celularity Inc's largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are C V Starr & Co Inc, Vanguard Capital Management LLC and Geode Capital Management, LLC. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
What is Celularity Inc's market cap?
On November 2, 2026, Celularity Inc's market capitalisation was about $23M and net debt of $33.2M. Market figures come from third-party market data and may be delayed.
Who are Celularity Inc's competitors?
In our Biotechnology peer group, the companies closest to Celularity Inc are Cytomx Therapeutics, Inc., Scynexis Inc, Proqr Therapeutics N.V., Keros Therapeutics, Inc. and Janux Therapeutics, Inc. The side-by-side comparison below sets their revenue, margins and growth against Celularity Inc's.